[{"address1": "321 Arsenal Street", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "339 217 0161", "website": "https://www.iteostherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 173, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michel  Detheux Ph.D.", "age": 57, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 1120393, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew A. Call M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 725481, "exercisedValue": 0, "unexercisedValue": 1074044}, {"maxAge": 1, "name": "Dr. David  Feltquate M.D., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "totalPay": 774444, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Gall", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 648001, "exercisedValue": 0, "unexercisedValue": 1259823}, {"maxAge": 1, "name": "Dr. Yvonne  McGrath Ph.D.", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Adi  Osovsky", "title": "Executive Vice President of Legal", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philippe  Brantegem", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.98, "open": 9.98, "dayLow": 9.96, "dayHigh": 10.185, "regularMarketPreviousClose": 9.98, "regularMarketOpen": 9.98, "regularMarketDayLow": 9.96, "regularMarketDayHigh": 10.185, "payoutRatio": 0.0, "beta": 1.515, "forwardPE": -1.7384616, "volume": 1098731, "regularMarketVolume": 1098127, "averageVolume": 1242590, "averageVolume10days": 1019250, "averageDailyVolume10Day": 1019250, "bid": 10.14, "ask": 10.22, "bidSize": 1, "askSize": 1, "marketCap": 389244544, "fiftyTwoWeekLow": 4.8, "fiftyTwoWeekHigh": 18.13, "priceToSalesTrailing12Months": 11.121273, "fiftyDayAverage": 7.7555, "twoHundredDayAverage": 8.610525, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -133343528, "profitMargins": 0.0, "floatShares": 22207987, "sharesOutstanding": 38273800, "sharesShort": 2533506, "sharesShortPriorMonth": 2531510, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.066199996, "heldPercentInsiders": 0.01135, "heldPercentInstitutions": 1.14689, "shortRatio": 1.02, "shortPercentOfFloat": 0.0851, "impliedSharesOutstanding": 38273800, "bookValue": 14.722, "priceToBook": 0.6908029, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -130811000, "trailingEps": -3.05, "forwardEps": -5.85, "enterpriseToRevenue": -3.81, "enterpriseToEbitda": 0.897, "52WeekChange": -0.33311474, "SandP52WeekChange": 0.09203708, "quoteType": "EQUITY", "currentPrice": 10.17, "targetHighPrice": 12.0, "targetLowPrice": 8.0, "targetMeanPrice": 11.0, "targetMedianPrice": 12.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 520368992, "totalCashPerShare": 13.596, "ebitda": -148648992, "totalDebt": 5053000, "quickRatio": 13.78, "currentRatio": 14.133, "totalRevenue": 35000000, "debtToEquity": 0.897, "revenuePerShare": 0.827, "returnOnAssets": -0.14541, "returnOnEquity": -0.23684, "grossProfits": 35000000, "freeCashflow": -47053876, "operatingCashflow": -99545000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -4.28306, "financialCurrency": "USD", "symbol": "ITOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "iTeos Therapeutics, Inc.", "longName": "iTeos Therapeutics, Inc.", "cryptoTradeable": false, "postMarketChangePercent": 0.0, "postMarketPrice": 10.17, "postMarketChange": 0.0, "regularMarketChange": 0.190001, "regularMarketDayRange": "9.96 - 10.185", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1242590, "fiftyTwoWeekLowChange": 5.37, "fiftyTwoWeekLowChangePercent": 1.11875, "fiftyTwoWeekRange": "4.8 - 18.13", "fiftyTwoWeekHighChange": -7.959999, "fiftyTwoWeekHighChangePercent": -0.43905127, "fiftyTwoWeekChangePercent": -33.311474, "earningsTimestamp": 1745872200, "earningsTimestampStart": 1754483400, "earningsTimestampEnd": 1754915400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.05, "epsForward": -5.85, "epsCurrentYear": -2.9714, "priceEpsCurrentYear": -3.422629, "fiftyDayAverageChange": 2.4145002, "fiftyDayAverageChangePercent": 0.3113275, "twoHundredDayAverageChange": 1.559475, "twoHundredDayAverageChangePercent": 0.18111265, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "corporateActions": [], "postMarketTime": 1749847451, "regularMarketTime": 1749844802, "exchange": "NGM", "messageBoardId": "finmb_663087242", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.90381, "regularMarketPrice": 10.17, "displayName": "iTeos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-06-14"}]